Welcome!

News Feed Item

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.html

PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

Summary

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

However, these classes represent the crowded, saturated, generic portion of the US atopic dermatitis market, with little room for innovative products. That said, the reliance on these agents will lead to an overall steady growth over the 10-year forecast period, with respective CAGRs of 1.2% and 0.5% for corticosteroids and moisturizers/emollients during this timeframe.

Scope

- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Atopic Dermatitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.2 Symptoms 18
4 Disease Management 20
4.1 Diagnosis 20
4.2 Treatment Overview 22
4.3 US 28
4.3.1 Diagnosis 28
4.3.2 Clinical Practice 30
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 34
5.3 Product Profiles - Major Brands 35
5.3.1 Protopic (tacrolimus) 35
5.3.2 Elidel 42
5.3.3 Cyclosporine (numerous generic names) 47
5.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 50
5.4 Product Profiles - Off-Label Therapies 52
5.4.1 Actimmune (interferon gamma-1b) 52
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Unmet Needs 57
6.2.1 A Systemic Drug for Severe Recalcitrant Patients 57
6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 59
6.2.3 A Drug that Effectively Controls Patients' Pruritus 60
6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis 61
6.2.5 A Drug that Induces Disease Remission 62
6.2.6 Improved Quality of Life for Both Patients and their Carers 63
6.3 Unmet Needs Gap Analysis 63
6.4 Opportunities 65
6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients 65
6.4.2 Predictive Tests for Patient Stratification 65
6.4.3 More Therapeutic Options that Address Patients' Pruritus 66
7 Pipeline Assessment 67
7.1 Overview 67
7.2 Promising Drugs in Clinical Development 69
7.2.1 Dupilumab (SAR231893/ REGN668) 70
7.2.2 AN2728 80
7.2.3 Phase II Pipeline Products 88
8 Market Outlook 89
8.1 Global Drivers and Barriers 89
8.1.1 Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease 89
8.1.2 Driver: The underserved severe refractory patient segment presents an untapped market opportunity 90
8.1.3 Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets 90
8.1.4 Driver: Atopic dermatitis presents an attractive patient population for drug developers 90
8.1.5 Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents 91
8.1.6 Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market 92
8.1.7 Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy 92
8.1.8 Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products 92
8.1.9 Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups 93
8.1.10 Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy 94
8.2 US 94
8.2.1 Forecast 94
8.2.2 Key Events 97
8.2.3 Drivers and Barriers 98
9 Appendix 101
9.1 Bibliography 101
9.2 Abbreviations 107
9.3 Methodology 109
9.4 Forecasting Methodology 109
9.4.1 Diagnosed Atopic Dermatitis Patients 109
9.4.2 Percent Drug-treated Patients 110
9.4.3 Drugs Included in Each Therapeutic Class 110
9.4.4 Launch and Patent Expiry Dates 110
9.4.5 General Pricing Assumptions 111
9.4.6 Individual Drug Assumptions 112
9.4.7 Generic Erosion 114
9.4.8 Pricing of Pipeline Agents 114
9.5 Physicians and Specialists Included in this Study 115
9.6 Primary Research - Prescriber Survey 116
9.7 About the Authors 117
9.7.1 Author 117
9.7.2 Global Head of Healthcare 118
9.8 About GlobalData 119
9.9 Disclaimer 119

1.1 List of Tables

Table 1: Symptoms of Atopic Dermatitis 19
Table 2: Treatment Guidelines for Atopic Dermatitis 25
Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27
Table 4: Referral Rates to a US Dermatologist, Split by Severity and Specialist Type, 2013 29
Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in the US, 2013 30
Table 6: Leading Treatments for Atopic Dermatitis, 2013 35
Table 7: Product Profile - Protopic 37
Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 38
Table 9: Protopic SWOT Analysis, 2013 41
Table 10: Product Profile - Elidel 43
Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 44
Table 12: Elidel SWOT Analysis, 2013 46
Table 13: Product Profile - Cyclosporine 48
Table 14: Cyclosporine SWOT Analysis, 2013 50
Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 51
Table 16: Product Profile - Actimmune 53
Table 17: Actimmune SWOT Analysis, 2013 55
Table 18: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 57
Table 19: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 64
Table 20: Late-Stage Atopic Dermatitis Pipeline, 2013 69
Table 21: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 70
Table 22: Product Profile - Dupilumab 72
Table 23: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of September 2013 74
Table 24: Dupilumab SWOT Analysis, 2013 79
Table 25: Product Profile - AN2728 81
Table 26: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29) 82
Table 27: AN2728 SWOT Analysis, 2013 87
Table 28: Phase II and Phase I Atopic Dermatitis Pipeline, 2013 88
Table 29: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 89
Table 30: Sales Forecasts ($m) for Atopic Dermatitis in the US, 2012-2022 96
Table 31: Key Events Impacting Sales for Atopic Dermatitis in the US, 2012-2022 97
Table 32: Atopic Dermatitis Market in the US - Drivers and Barriers, 2012-2022 98
Table 33: Key Launch Dates 110
Table 34: Key Patent Expiries 110
Table 35: Physicians Surveyed, By Country 116

1.2 List of Figures

Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin 16
Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis 23
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022 69
Figure 4: Sales for Atopic Dermatitis in the US by Drug Class, 2012-2022 97


Read the full report:
PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...